Abbreviations used in this paper: AIF = apoptosis-inducing factor; CCD = charge-coupled device; DIC = differential-interference contrast; dsRNA = double-stranded RNA; HIAP = human inhibitor of apoptosis protein; mAb = monoclonal antibody; PARP = poly (adenosine diphosphate ribose) polymerase; PBS = phosphate-buffered saline; siRNA = small interfering RNA; XIAP = X chromosome-linked IAP. g/ml streptomycin and 100 U/ml penicillin) at 37˚C in a humidified atmosphere (95% air/5% CO 2 ).
Materials Used in the Study
The C2-ceramide was obtained from Upstate Biotechnology (Lake Placid, NY). For the immunochemical studies we used mouse mAb to AIF (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), Alexa Fluor-488-labeled rabbit anti-mouse immunoglobulin G antibody (Molecular Probes, Inc., Eugene, OR), Mitotracker Red CMX Ros (Molecular Probes, Inc.), and TO-PRO-3 iodide (Molecular Probes, Inc.).
Cell Viability
To evaluate the cytotoxicity of C2-ceramide, four kinds of human glioma cells, each containing 5000 cells in 100 l of culture medium, were seeded into 96-well plates (BD Biosciences, San Jose, CA) and then incubated at 37˚C in a humidified atmosphere of 95% air/ 5% CO 2 for 24 hours. After C2-ceramide treatment at a final concentration of 25 M in 100 l of serum-free medium, the viability of the cells was determined by performing a WST-1 assay (Roche Diagnostics, Indianapolis, IN) at a definite time. Ten microliters of WST-1 solution was added to each well. After incubation for 1 hour at 37˚C, the absorbance difference between 450 and 655 nm was measured using a microplate reader (Benchmark Microplate Reader; Bio-Rad Laboratories, Hercules, CA) and the percentage of viability was calculated as follows: (experiment Ϫ blank)/(control Ϫ blank) ϫ 100%, where experiment is the sample's difference in absorbance between 450 and 655 nm, blank is a medium containing WST-1 solution without cells, and control is the signal from wells containing cells and 0.1% ethanol, but no serum medium.
Morphological Changes
Before C2-ceramide treatment, four kinds of human glioma cells were seeded into a glass-bottom culture dish (MatTec, Ashland, MA) and later incubated at 37˚C in a humidified atmosphere of 95% air/5% CO 2 for 24 hours. After 24 hours of exposure to C2-ceramide (25 M) or 0.1% ethanol, the glioma cells were observed with the aid of an inverted microscope equipped with a ϫ10 DIC objective lens and a ϫ1.6 insertion lens (Axiovert 135; Carl Zeiss, Göttingen, Germany). The microscopic images were sent to an image processor and controller via a CCD camera. Digitalized imaging data were captured with the aid of a computer imaging system (KS400 [version 3.00]; Carl Zeiss Vision GmbH, Hallbergmoos, Germany).
Assay of Caspase-3 and Caspase-8 Activities
A Caspase-3 and -8 Colorimetric Protease Assay Kit (Medical and Biological Laboratories Co., Ltd., Nagoya, Japan) was used to measure caspase-3 and -8 activities at various points after treatment. Cells treated with C2-ceramide were collected and lysed using cell lysis buffer, after which the supernatants were collected and measured using a DC Protein Assay kit (Bio-Rad Laboratories). Equal amounts of protein (50 g) were diluted in 50 l of cell-dilution buffer. Added to each sample was DEVD-pNa (caspase-3) or IETDpNa (caspase-8) (final concentration of the substrate 200 M). The samples were incubated at 37˚C for 1 hour. After incubation, the optical density at 400 nm was measured using a microplate reader (BioRad Laboratories).
Changes in the Mitochondrial Membrane Potential
To assess changes in the mitochondrial membrane potential, we used a tracking system (MitoTracker Orange CMTMRos; Molecular Probes, Inc.). Human glioma cells were seeded into a glass-bottomed culture dish and incubated at 37˚C under humidified conditions for 24 hours. After changing to a dye-containing medium (Orange CMTMRos, 200 nM), the cells were incubated for 15 minutes at 37˚C. After washing the labeled cells, minimal essential medium containing 25 M C2-ceramide or 0.1% ethanol (control) was added to the dishes. Cells were observed using fluorescence microscopy and captured by the CCD camera after incubation. In each image, the cell bodies were circled, identifying them as regions of interest from which cellular fluorescence intensity could then be measured using imaging software (NIH Image [version 1.63]; National Institutes of Health, Bethesda, MD). Data were collected as background (cell-free regions)-subtracted fluorescence intensity.
Translocation of AIF
To confirm the localization of AIF protein, tumor cells (SKMG1 and U251SP) were grown on poly-L-lysine-coated glass coverslips (ASAHI Techno Glass Corp., Tokyo, Japan) in 24-well flat-bottom tissue culture plates (BD Biosciences) for 24 hours, after which the cells were exposed to C2-ceramide (25 M) for an additional 24 hours.
At the end of the incubation period, the cells were centrifuged on glass coverslips and stained for mitochondria with 50 nM Mitotracker Red CMXRos (Molecular Probes, Inc.) for 30 minutes at 37˚C. The cells were then fixed for 15 minutes in 4% paraformaldehyde, washed in PBS, and permeabilized with 0.1% sodium dodecyl sulfate. The RNAs were digested by the addition of RNase (final concentration 0.5 mg/ml) to a blocking solution (PBS with 1% bovine serum albumin) for 30 minutes at room temperature. The cells were immersed in the blocking solution (30 minutes at room temperature) and incubated in AIF antibody solution (concentration 1:200) (2 hours at room temperature). They were then washed with three changes of PBS and incubated in Alexa Fluor 488-labeled secondary antibody solution (concentration 1:300) containing TO-PRO-3 iodide (final 1 M) for 1 hour at room temperature. The negative control consisted of slides to which only the secondary antibody containing TO-PRO-3 iodide was added. Finally, coverslips were washed in PBS, mounted on glass slides over a drop of Perma Fluor (Immunon, Pittsburgh, PA), and stored at 4˚C in the dark until observation. The slides were examined under a Nikon Eclipse E600 microscope with a Plan Apo 60ϫ/1.4 oil immersion lens (Nikon Corp., Tokyo, Japan). The system was equipped with a laser confocal device (Radiance 2000; Bio-Rad Laboratories), composed of an Argon ion laser (488 nm excitation), a green HeNe laser (543 nm excitation), a red laser diode (638 nm excitation), and filters (HQ530/60, HQ600/50, and HQ660LP). Image processing was performed using LaserSharp 2000 computer software (Bio-Rad Laboratories).
Western Blot Analysis
Treated cells were collected by scraping in PBS and were pelleted before lysing in a buffer containing the protease inhibitors phenylmethylsulfonyl fluoride (100 g/ml), aprotinin (1 g/ml), and leupeptin (1 g/ml). Lysate protein concentrations were determined using a Bio-Rad DC Protein Assay kit. Protein samples were denatured in gel-loading buffer (New England Biolabs, Inc., Beverly, MA) at 99˚C for 5 minutes. Equal amounts of protein (65 g) were applied to each well and electrophoresed on 7.5% polyacrylamide gel or 14 to 16% polyacrylamide gradient gel (both from Daiichi Pure Chemicals, Ltd., Tokyo, Japan). Proteins were transferred to polyvinylidene difluoride membranes (Millipore Corp., Billerica, MA); blocked with 10% lowfat milk; and incubated with primary antibody against caspase-7 mAb (clone 4G2; Pharmingen, San Diego, CA), caspase-3 polyclonal antibody (Pharmingen), PARP polyclonal antibody (Cell Signaling Technology, Inc., Beverly, MA), and XIAP mAb (clone 48; Pharmingen), after which the proteins were washed and blotted with species-specific secondary antibodies (mouse and rabbit) (Santa Cruz Biotechnology). The blotted proteins were visualized using an enhanced chemiluminescence detection system (Amersham Biosciences, Piscataway, NJ).
Determination of DNA Fragmentation
We monitored the C2-ceramide-induced intranucleosomal DNA fragmentation. Cultured human glioma cells (10 6 ) were treated with 0.1% ethanol or 25 M C2-ceramide for 12, 24, and 48 hours. To evaluate intranucleosomal DNA fragmentation, we used the Apoptosis Ladder Detection Kit (Wako Pure Chemical Industries, Osaka, Japan). Glioma cells were incubated with 25 M C2-ceramide or 0.1% ethanol for 12 to 48 hours. Genomic DNA was extracted according to the manufacturer's protocol. The extracted DNA was electrophoresed on 1.5% agarose gel and visualized with SYBR Green I.
Small Interfering RNA Transfection
Tumor cells were transfected with siRNA for XIAP messenger RNA in accordance with the following protocol. The siRNA sequences targeting XIAP (Gene Bank No. U45880) corresponded to coding regions 111 to 131 relative to the first nucleotide of the start codon. The nucleotides included sense 5Ј-GUGGUAGUCCUGUUUCAGCdTdT-3Ј and antisense 5Ј-GCUGAAACAGGACUACCACdTdT-3Ј. The RNAs were chemically synthesized by JBioS, Inc. (Saitama, Japan). For the annealing of dsRNA, 100 M sense and antisense RNAs were incubated in annealing buffer (100 mM potassium acetate, 2 mM magnesium acetate, 30 mM HEPES-KOH at pH 7.4) for 1 minute at 90˚C, 1 minute at 70˚C, and followed by 1 hour at 37˚C. The day before transfection, 10 5 trypsinized cells were plated to each well of six-well Falcon plates (BD Biosciences). After 24 hours of plating, dsRNA was mixed with Oligofectamine reagent (Invitrogen, Carlsbad, CA) in OptiMEM medium (Gibco-BRL, Gaithersburg, MD). Cultured cells were washed with medium without serum and added to the dsRNA-Oligofectamine mixture (final concentration 50 nM dsRNA). Up to 10% fetal bovine serum was added to the medium 4 hours later. After the cells were incubated at 37˚C under humidified conditions for 48 hours, they were treated with 25 M C2-ceramide and incubated for various periods (6-36 hours). The cells were then lysed in lysis buffer and the lysates were subjected to Western blot analysis for expressions of caspase-7, caspase-3, PARP, and XIAP.
Results

Antitumor Activity of C2-Ceramide in Human Glioma Cells
To screen human glioma cells for their susceptibility to C2-ceramide, SKMG1, U87MG, U251SP, and T98G cells were exposed to C2-ceramide for various periods. Both SKMG1 and U87MG cells demonstrated a high susceptibility to C2-ceramide, resulting in cell death (Fig. 1) . By 18 hours, cell viability had decreased 40% from that of control. In contrast, U251SP and T98G cells demonstrated a high resistance to C2-ceramide (Fig. 1) .
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Morphological Changes in Human Glioma Cells Exposed to C2-Ceramide
Morphological changes in human glioma cells exposed to C2-ceramide were observed for 24 hours by performing DIC microscopy. Compared with the 0.1% ethanol-treated cells, those cells exposed to C2-ceramide underwent morphological changes, for example, membrane blebbing, ballooning, and the appearance of apoptotic bodies in SKMG1 (Fig. 1A-2 ) and U87MG (Fig. 1B-2 ) cells. In other human glioma cells (U251SP and T98G cells), no morphological changes occurred with or without C2-ceramide exposure (Fig. 1C-2 
and D-2).
Caspase-3 and Caspase-8 Activities During Exposure to C2-Ceramide
To determine whether C2-ceramide induction of cell death depended on its caspase pathway, we measured the activities of caspase-3 and -8 in four groups of glioma cells exposed to C2-ceramide. Treatment of those cells with 25 M C2-ceramide resulted in no significant increases in caspase-3 and -8 activities compared with control cells (data not shown). Even when cells from the C2-ceramide-sensitive cell lines SKMG1 and U87MG died, neither caspase-3 nor caspase-8 was activated (data not shown).
Mitochondrial Membrane Potential of Human Glioma Cells Exposed to C2-Ceramide
To evaluate whether mitchondrial conditions differed between C2-ceramide-sensitive (SKMG1) and -resistant (U251SP) cells, the mitochondrial membrane potential was assessed using MitoTracker Orange CMTMRos staining. Treatment of cells with 25 M C2-ceramide caused a significant increase in mitochondrial fluorescence after 9 hours in the sensitive SKMG1 cells (Fig. 2) ; however, the resistant U251SP cells displayed the same intensity as control cells at various incubation times (Fig. 2) . These data indicated that the mitochondrial membrane potential in SKMG1 cells was reduced by exposure to C2-ceramide.
Translocation of AIF Into the Nucleus
Confocal laser microscopy revealed that AIF translocated into the nucleus after 24 hours of incubation in SKMG1 cells exposed to C2-ceramide (Fig. 3) . Light blue regions demonstrated green (Alexa Fluor-488) overlapping the blue (TO-PRO-3), indicating that AIF had translocated into the nucleus (Fig. 3 lower left) . In contrast, control SKMG1 cells displayed a perinuclear localization of AIF (Fig. 3 upper  left) . The C2-ceramide-resistant U251SP cells showed no translocation of AIF into the nucleus (Fig. 3 upper and lower right) .
Fragmentation of DNA in Human Glioma Cells Exposed to C2-Ceramide
Cell death induced by C2-ceramide was morphologically indicative of the progression of apoptosis. In fact, internucleosomal DNA fragmentation was observed in C2-ceramide-sensitive SKMG1 cells (Fig. 4 left) . Nevertheless, C2-ceramide induced no DNA fragmentation whatsoever in resistant U251SP cells (Fig. 4 right) .
Caspase-7 and PARP in Human Glioma Cells Exposed to C2-Ceramide
Western blot analysis confirmed the expression of 35-kD procaspase-7, 116-kD full-length PARP ( procaspase-3 (data not shown) under control conditions in both SKMG1 and U251SP cells. Following treatment with C2-ceramide, there was a time-dependent cleavage of caspase-7 and a downregulation of full-length PARP in C2-ceramide-sensitive SKMG1 cells ( Fig. 5 left) ; no such cleavage of caspase-7 or downregulation of PARP was expressed in C2-ceramide-resistant U251SP cells (Fig. 5 right) .
Expression of XIAP in Human Glioma Cells
Western blot analysis was performed to verify XIAP expression in human glioma cells (SKMG1, U87MG, U251SP, T98G, U251-MG, and SKAO2), mouse melanoma cells (B16F1), and human T-cell leukemia cells (Jurkat). Even if the applied protein volume was the same in each line, the XIAP protein levels were much higher in human glioma cell lines than in the other two types of cells (Fig. 6A) .
Effect of XIAP Inhibition on C2-Ceramide-Resistant U251SP Cells
To determine whether the inhibition of XIAP was effective in inducing cell death in C2-ceramide-resistant cell lines, siRNA targeting of the XIAP gene was used. Treatment with siRNA (50 nM) resulted in a significant decrease in XIAP protein (Fig. 6B) .
Next, C2-ceramide-resistant U251SP cells treated with siRNA were exposed to C2-ceramide, and the changes in caspase activation were analyzed, revealing an active 17-kD caspase-7 fragment 24 hours after treatment (Fig. 7  upper) . Full-length 116-kD PARP had also cleaved into a C-terminal 89-kD PARP apoptotic fragment concomitantly with the formation of the active 17-kD caspase-7 fragment in U251SP cells treated with siRNA (Fig. 7 lower) . Western blot analysis of caspase-3, however, showed no formation of any active 12-kD caspase-3 fragment in U251SP cells treated with C2-ceramide after siRNA pretreatment, even in SKMG1 cells that were treated with C2-ceramide (data not shown).
Electrophoretic patterns of oligonucleosomal DNA laddering were detected in U251SP cells treated with both siRNA and C2-ceramide, indicating that C2-ceramide could induce apoptotic cell death in C2-ceramide-resistant human glioma cells (Fig. 8) .
Discussion
In the present study, in contrast to hematopoietic cells, C2-ceramide could not induce apoptosis in the majority of human glioma cells except for SKMG1. The detailed mechanisms of resistance to ceramide in human glioma cells remain poorly understood.
In C2-ceramide-sensitive human glioma cells (SKMG1 cells), caspase-7 was activated, but caspase-8 and -3 were not. In those cells, the loss of the mitochondrial membrane potential and AIF translocation into the nucleus were also detected, resulting in a high-molecular-mass DNA fragmentation and marginal chromatin condensation. The same results were observed by Susin, et al. 32 The role of caspase-7 activation still remains unknown in C2-ceramidesensitive human glioma cells, however, because caspase-3, which is located downstream from caspase-7, was not ac- c release was required. 13, 14 On the other hand, in C2-ceramide-resistant human glioma cells (U251SP and T98G cells), C2-ceramide failed to activate caspase-8, -3, or -7. These results indicate that usual apoptotic pathways, which were induced by some death receptors and caspases, played no role in C2-ceramide-resistant human glioma cells.
We also investigated the expression in human glioma cells of IAPs, which are a counterpart to caspases. The IAP family is defined by a novel conserved motif termed the "baculoviral IAP repeat." In humans, six IAP-like proteins have been identified and designated XIAP, HIAP-1, HIAP-2, neuronal apoptosis inhibitory protein, survivin, and apollon. 3, 5, 11, 15, 19, 24, 26, 34 The most potent caspase inhibitor, XIAP, directly binds and inhibits caspase-3, -7, and -9. 6, 9, 10, 25 Recent studies have demonstrated that the downregulation of XIAP by using an antisense XIAP-expressing adenovirus effectively induces apoptosis in chemoresistant ovarian cancer cells. 28 The proteins XIAP, HIAP-1, and HIAP-2 are widely expressed by glioma cell lines, and it has been also reported that IAPs are often upregulated in brain tumors. 1, 17, 35 These proteins may play a role in the striking resistance of gliomas to the induction of apoptosis by radiotherapy and chemotherapy. Such findings indicate that human glioma cells resistant to C2-ceramide may be able to induce apoptosis via XIAP downregulation. As another possibility, there are some reports that the C2-ceramide-mediated apoptosis of gliomas was inhibited by Bcl-2. 36 Next we investigated the efficacy of IAP inhibition in human glioma cells to overcome the resistance to apoptosis. First, we tried to knock down XIAP in C2-ceramide-resistant human glioma cells by using a newly established approach involving siRNA, reported by Elbashir, et al. 12 The transfection of siRNA targeting of the XIAP gene remarkably reduced the production of XIAP protein in human glioma cells. The C2-ceramide-resistant U251SP cells initially inhibited XIAP production by siRNA and then exposed to C2-ceramide, displayed apoptotic events, that is, activation of caspase-7, cleavage of PARP, and DNA fragmentation (Figs. 7 and 8 ).
In conclusion, inhibition by endogenous caspase inhibitors, such as XIAP, can render C2-ceramide-resistant human glioma cells sensitive to C2-ceramide through the activation of caspase-dependent pathways.
